‘The second wave may be even worse because people may not follow the requirements’: Dr. Kass

On Monday, Gilead Sciences announced that it would charge more than $2,340 for the use of its remdesivir per patient. Dr Dara Kass, Associate Professor of Emergency Medicine at Columbia University Medical Center, joins The First Trade to break down Gilead Sciences’ announcement, developments in the vaccine race, and reopenings in the U.S.